Novel genomic score predicts survival with immune checkpoint blockade in neuroendocrine neoplasms

#4291

Introduction: Immune checkpoint inhibition (ICI) has activity in Grade 3 (G3) neuroendocrine neoplasms (NENs) but predictive biomarkers of overall survival (OS) are currently lacking.

Aim(s): We characterised outcomes in NENs treated with anti-PD-1 and anti-CTLA-4 ICI and derived a genomic scoring system to predict OS.

Materials and methods: NENs who received ³1 dose of ipilimumab and/or nivolumab between 9/1/2017 and 3/31/2023 were included. An overall genomic score (GS-O) was derived based on alterations in 70 genes that are known predictors of response and resistance to ICI. Separately, GS-O was calculated in a cohort of NENs treated with chemotherapy alone.

Conference:

Presenting Author:

Authors: Brar T, Sukrithan V, Le D, Xu M, Olowookere C,

Keywords: Neuroendocrine Neoplasm, Immunotherapy, Ipilimumab, Nivolumab, Immune checkpoint inhibitor, biomarker, genomic score,